Clinical Phenotypes and Personalized Nutritional Strategies in Metabolic Dysfunction-Associated Steatotic Liver Disease
DOI:
https://doi.org/10.64784/341Palabras clave:
metabolic dysfunction-associated steatotic liver disease, MASLD, metabolic dysfunction, hepatic steatosis, clinical phenotypes, obesity, insulin resistance, type 2 diabetes mellitus, lean MASLD, personalized nutrition, Mediterranean diet, weight loss, visceral adiposity, dyslipidemia, lifestyle interventionResumen
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent metabolic disorder characterized by substantial clinical heterogeneity and frequent association with obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, visceral adiposity, and alterations in body composition. This study analyzed the principal clinical phenotypes of MASLD and their relationship with personalized nutritional interventions through a structured analytical review of clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and observational studies. The evidence showed marked differences in disease prevalence and metabolic characteristics across lean, overweight, obese, and diabetic populations. Sustained weight loss was associated with progressive hepatic improvement, with reductions of approximately 5% linked to decreased liver fat, 7–10% to improvement in inflammatory activity, and reductions of 10% or greater to greater probability of fibrosis improvement. Dietary quality was also relevant independently of absolute weight reduction, particularly through Mediterranean-style patterns, reduced intake of added sugars and ultra-processed foods, and replacement of saturated fats with unsaturated sources. Lean MASLD represented a distinct phenotype in which metabolic dysfunction may persist despite normal body mass index, requiring greater emphasis on body composition, visceral adiposity, physical activity, and preservation of lean mass rather than aggressive caloric restriction. Overall, the findings support a phenotype-oriented model of nutritional management in which common evidence-based lifestyle principles are maintained while the intensity and priority of specific interventions are adapted to individual metabolic, hepatic, anthropometric, and behavioral characteristics. Further prospective studies are required to determine whether personalized nutritional strategies improve long-term fibrosis progression, cardiovascular outcomes, liver-related complications, and mortality.
Referencias
• Brunetto, M. R., Salvati, A., Petralli, G., & Bonino, F. (2023). Nutritional intervention in the management of non-alcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology, 62–63, 101830. doi:10.1016/j.bpg.2023.101830.
• Cariou, B. (2022). The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism, 24(Suppl. 2), 15–27. doi:10.1111/dom.14651.
• European Association for the Study of the Liver, European Association for the Study of Diabetes, & European Association for the Study of Obesity. (2024). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 81(3), 492–542. doi:10.1016/j.jhep.2024.04.031.
• Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021). Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Seminars in Liver Disease, 41(3), 225–234. doi:10.1055/s-0041-1723751.
• Lonardo, A., Arab, J. P., & Arrese, M. (2021). Perspectives on precision medicine approaches to NAFLD diagnosis and management. Advances in Therapy, 38(5), 2130–2158. doi:10.1007/s12325-021-01690-1.
• Long, M. T., Noureddin, M., & Lim, J. K. (2022). AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review. Gastroenterology, 163(3), 764–774.e1. doi:10.1053/j.gastro.2022.06.023.
• Nam, H., Yoo, J.-J., Cho, Y., Kang, S. H., Ahn, S. B., Lee, H.-W., Jun, D. W., Song, D. S., & Choi, M. (2023). Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. Digestive and Liver Disease, 55(9), 1178–1186. doi:10.1016/j.dld.2022.12.013.
• Properzi, C., O’Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018). Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial. Hepatology, 68(5), 1741–1754. doi:10.1002/hep.30076.
• Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Castro Narro, G. E., Chowdhury, A., Cortez-Pinto, H., . . . Newsome, P. N. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966–1986. doi:10.1097/HEP.0000000000000520.
• Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797–1835. doi:10.1097/HEP.0000000000000323.
• Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013). The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology, 59(1), 138–143. doi:10.1016/j.jhep.2013.02.012.
• Sato-Espinoza, K., Chotiprasidhi, P., Huaman, M. R., & Díaz-Ferrer, J. (2024). Update in lean metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology, 16(3), 452–464. doi:10.4254/wjh.v16.i3.452.
• Semmler, G., Datz, C., & Trauner, M. (2023). Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease. Clinical and Molecular Hepatology, 29(Suppl.), S244–S260. doi:10.3350/cmh.2022.0364.
• Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149(2), 367–378.e5. doi:10.1053/j.gastro.2015.04.005.
• Wei, X., Lin, B., Huang, Y., Yang, S., Huang, C., Shi, L., Liu, D., Zhang, P., Lin, J., Xu, B., Guo, D., Li, C., He, H., Liu, S., Xue, Y., Xu, Y., & Zhang, H. (2023). Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial. JAMA Network Open, 6(3), e233513. doi:10.1001/jamanetworkopen.2023.3513.
• Yaskolka Meir, A., Rinott, E., Tsaban, G., Zelicha, H., Kaplan, A., Rosen, P., Shelef, I., Youngster, I., Shalev, A., Blüher, M., Ceglarek, U., Stumvoll, M., Tuohy, K., Diotallevi, C., Vrhovsek, U., Hu, F., Stampfer, M., & Shai, I. (2021). Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial. Gut, 70(11), 2085–2095. doi:10.1136/gutjnl-2020-323106.
• Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021). Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology, 18(11), 770–786. doi:10.1038/s41575-021-00472-y.
• Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 77(4), 1335–1347. doi:10.1097/HEP.0000000000000004.
• Zelber-Sagi, S. (2021). Dietary treatment for NAFLD: New clinical and epidemiological evidence and updated recommendations. Seminars in Liver Disease, 41(3), 248–262. doi:10.1055/s-0041-1729971.
• Zelber-Sagi, S., Grinshpan, L. S., Ivancovsky-Wajcman, D., Goldenshluger, A., & Gepner, Y. (2022). One size does not fit all; practical, personal tailoring of the diet to NAFLD patients. Liver International, 42(8), 1731–1750. doi:10.1111/liv.15335.
